XPO1 and plasma cell myeloma: Thus, nuclear–cytoplasmic shuttling currently represents an attractive therapeutic target investigated in different tumor types [36], as recently demonstrated by the Food and Drug Administration approval of the exportin 1 inhibitor selinexor for multiple myeloma [29].